AVR Anteris Technologies Global Corp.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 2011514 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY-28.3%
TTM EPS YoY36.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin75.8%
Operating margin-4,880.4%
Net margin-4,637.5%
FCF margin-4,008.4%
EBITDA margin-4,802.4%
Returns
ROE-93.8%
ROA-76.8%
ROIC (approx.)-3,856.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets13.5%
Debt / equity0.00x
Current ratio12.45x
Interest coverage-615.19x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue110.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.91M | $2.70M |
| Cost of revenue | $569,000 | $1.44M |
| Gross profit | $1.34M | $1.27M |
| R&D expense | $69.12M | $51.45M |
| SG&A expense | $26.12M | $28.19M |
| Operating income | -$93.89M | -$78.37M |
| Interest expense | $73,000 | $47,000 |
| Pretax income | -$94.22M | -$75.97M |
| Income tax | $0 | $0 |
| Net income | -$94.14M | -$76.29M |
| EBITDA | -$92.23M | -$76.86M |
| EPS (basic) | -2.55 | -3.68 |
| EPS (diluted) | -2.55 | -3.68 |
| Weighted avg. shares (diluted) | 36.91M | 20.25M |
| Balance sheet | ||
| Cash & equivalents | $6.70M | $70.46M |
| Receivables | $32,000 | $208,000 |
| Inventory | $152,000 | $513,000 |
| Current assets | $15.68M | $74.65M |
| PP&E, net | $5.26M | $4.77M |
| Intangibles | $65,000 | $189,000 |
| Total assets | $23.00M | $80.70M |
| Current liabilities | $21.37M | $16.56M |
| Short-term debt | $16,000 | $3,000 |
| Long-term debt | $22,000 | $0 |
| Total debt | $38,000 | $3,000 |
| Total liabilities | $23.25M | $18.02M |
| Shareholders' equity | -$93,000 | $62.76M |
| Net debt | -$6.66M | -$70.45M |
| Shares outstanding | 41.58M | 35.94M |
| Cash flow statement | ||
| Operating cash flow | -$77.80M | -$61.24M |
| Capital expenditure | $1.95M | $2.27M |
| Free cash flow | -$79.76M | -$63.51M |
| Investing cash flow | -$596,000 | -$2.28M |
| Financing cash flow | $20.55M | $112.83M |
| Depreciation & amortization | $1.66M | $1.51M |
| Stock-based compensation | $7.78M | $6.52M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.